Garber AM, Sculpher MJ. Chapter eight: cost effectiveness and payment policy. In: Pauly MV, Mcguire TG, Barros PP, editors. Handbook of health economics, vol. 2. Amsterdam: Elsevier; 2011. p. 471–97.
Rappange DR, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26(10):815–30.
van Lier LI, et al. Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ. 2018;19(7):993–1008.
Drummond MF, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.
Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1–31.
Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33–64.
Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ. 2004;13(5):417–27.
Nyman JA. More on survival consumption costs in cost-utility analysis. Health Econ. 2006;15:319–22.
Richardson JR, Olsen JA. In defence of societal sovereignty: a comment on Nyman ‘the inclusion of survivor consumption in CUA’. Health Econ. 2006;15:311–3.
Gandjour A. Consumption costs and earnings during added years of life: a reply to Nyman. Health Econ. 2006;15:315–7.
Lundin D, Ramsberg J. On survival consumption costs: a reply to Nyman. Health Econ. 2008;17:293–7.
van Baal PHM, et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a “perfect” cost-utility ratio. Health Econ. 2007;16:421–33.
Liljas B, Karlsson GS, Stalhammar N. On future non-medical costs in economic evaluations. Health Econ. 2008;17:579–91.
Lee RH. Future costs in cost effectiveness analysis. J Health Econ. 2008;27:809–18.
Meltzer D. Response to “Future costs and the future of cost-effectiveness analysis”. J Health Econ. 2008;27:822–5.
Feenstra TL, et al. Future costs in economic evaluation: a comment on Lee. J Health Econ. 2008;27(6):1645–9.
Nyman JA. Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone. Health Econ. 2011;20(1):56–67.
Liljas B. Welfare, QALYS, and costs: a comment. Health Econ. 2011;20(1):68–72.
van Baal PHM, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2016;25(2):237–48.
Morton A, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933–8.
van Baal P, et al. Future unrelated medical costs need to be considered in cost-effectiveness analysis. Eur J Health Econ. https://doi.org/10.1007/s10198-018-0976-0. (Epub ahead of print).
Brouwer WB, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38.
Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2(2):147–57.
Meltzer D, Johannesson M. Inconsistencies in the ‘societal perspective’ on costs of the panel on cost-effectiveness in health and medicine. Med Decis Mak. 1999;19(4):371–7.
Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester: Wiley; 2007.
Grima DT, et al. Cost-effectiveness analysis of therapies: a case for excluding dialysis costs. Pharmacoeconomics. 2012;30(11):981–9.
van Baal PHM, Meltzer D, Brouwer W, et al. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. Pharmacoeconomics. 2013;31(5):369–73.
Weinstein MC, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8.
van Baal P, et al. Should cost effectiveness analyses for NICE always consider future unrelated medical costs? BMJ. 2017;10(359):j5096. https://doi.org/10.1136/bmj.j5096.
Weinstein MC, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—modeling studies. Value Health. 2003;6(1):9–17.
Cobiac LJ, et al. Taxes and subsidies for improving diet and population health in Australia: a cost-effectiveness modelling study. PLoS Med. 2017;14(2):e1002232. https://doi.org/10.1371/journal.pmed.1002232.
van Baal PH, et al. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health. 2008;11(7):1033–40.
Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337(15):1052–7.
Gandjour A, Lauterbach KW. Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ. 2005;24(2):715–24.
van Baal PHM, et al. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29(3):175–87.
Zweifel P, Felder S, Meiers M. Ageing of population and health care expenditure: a red herring? Health Econ. 1999;8(6):485–96.
van Baal PHM, et al. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20(4):432–45.
Assaria M. Health care costs in the English NHS: reference tables for average annual NHS spend by age, sex and deprivation group. CHE research paper 147. York: Centre for Health Economics, University of York; 2017.
van Baal PH, Hoogendoorn M, Fischer A. Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. Prev Med. 2016;85:78–83.
Briggs ADM, et al. Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling. PLoS One. 2018;13(5):e0197257. https://doi.org/10.1371/journal.pone.0197257.
Meltzer D. Future costs in medical cost-effectiveness analysis. In: Jones AM, editor. The Elgar companion to health economics. 2nd ed. Cheltenham: Edward Elgar; 2012.
Kruse M, Sorensen J, Gyrd-Hansen D. Future costs in cost-effectiveness analysis: an empirical assessment. Eur J Health Econ. 2012;13:63–70.
Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Mak. 1997;17(4):382–9.
Manns B, et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ. 2003;12(11):949–58.
Meltzer D, et al. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care. 2000;38(6):679–85.
Ramos IC, et al. Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current Dutch. Value Health. 2017;20(10):1260–9.
Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost–benefit analysis? J Health Econ. 1999;18(6):681–708.
Cutler D, Deaton A, Lleras-Muney A. The determinants of mortality. J Econ Perspect. 2006;20(3):97–120.
Tilling C, et al. In or out? Income losses in health state valuations: a review. Value Health. 2010;13(2):298–305.
Adarkwah CC, Sadoghi A, Gandjour A. Should cost-effectiveness analysis include the cost of consumption activities? An empirical investigation. Health Econ. 2016;25(2):249–56.
Nyman J. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1):2381468318765162. https://doi.org/10.1177/2381468318765162.
Drost RMWA, et al. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251–60.
Ekman M. Consumption and production by age in Sweden: basic facts and health economic implications. Studies in health economics: modelling and data analysis of costs and survival. Stockholm: Stockholm School of Economics; 2002.
Gold MR, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
Borg S, et al. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncol. 2016;55(5):554–60.
Gros B, Soto Álvarez J, Ángel Casado M. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):465–9.
Zorginstituut Nederland. Guideline for economic evaluations in healthcare. 2016.
The Dental and Pharmaceutical Benefits Agency. General guidelines for economic evaluations. 2003.
Svensson M, Hultkrantz L. A comparison of cost-benefit and cost-effectiveness analysis in practice: divergent policy practices in Sweden. Nordic J Health Econ. 2017;5(2):41–53.
Heintz E, et al. The impact of health economic evaluations in Sweden. Z Evid Fortbild Qual Gesundh. 2014;108(7):375–82.
Davidson T. Experiences of including costs of added life years in health economic evaluations in Sweden. In: Pirhonen L, Davidson T, editors. Farmeconomia: health economics and therapeutic pathways. 2014;15(2):45–53.
The Dental and Pharmaceutical Benefits Agency. Ändring i Läkemedelsförmånsnämndens allmänna råd (LFNAR 2003:2) om ekonomiska utvärderingar. 2015.
Ändring i Tandvårds - och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar. 2017.
Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
Meltzer DO, Smith PC. Chapter seven: theoretical issues relevant to the economic evaluation of health technologies. In: Pauly MV, Mcguire TG, Barros PP, editors. Handbook of health economics, vol. 2. Amsterdam: Elsevier; 2011. p. 433–69.
National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2013.
Russell LB. Is prevention better than cure? Washington. DC: Brookings Institution; 1986.
Nord E, Lamøy C. Including future consumption and production in economic evaluation of interventions that save life-years: commentary. Pharmacoecon Open. 2018. https://doi.org/10.1007/s41669-018-0079-y. (Epub ahead of print).
Reckers-Droog VT, van Exel NJA, Brouwer WBF. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Policy. 2018;122(6):621–9.
van Baal P, et al. A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2018. https://doi.org/10.1002/hec.3831. (Epub ahead of print).
Brouwer WBF, et al. When is it too expensive? Cost-effectiveness thresholds and health care decision making. Eur J Health Econ. 2018.
Brouwer WBF, Baltussen M, Rutten FFH. A dollar is a dollar is a dollar: or is it? Value Health. 2006;9(5):341–7.